GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » EPS without NRI

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) EPS without NRI : $-1.12 (TTM As of Mar. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings EPS without NRI?

Entasis Therapeutics Holdings's earnings per share without non-recurring items for the three months ended in Mar. 2022 was $-0.32. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was $-1.12.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 55.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 31.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Entasis Therapeutics Holdings's EPS without NRI or its related term are showing as below:

ETTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 13.5   Med: 36.1   Max: 55.4
Current: 55.4

During the past 6 years, Entasis Therapeutics Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 55.40% per year. The lowest was 13.50% per year. And the median was 36.10% per year.

ETTX's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.1 vs ETTX: 55.40

Entasis Therapeutics Holdings's EPS (Diluted) for the three months ended in Mar. 2022 was $-0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-1.12.

Entasis Therapeutics Holdings's EPS (Basic) for the three months ended in Mar. 2022 was $-0.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $-1.12.


Entasis Therapeutics Holdings EPS without NRI Historical Data

The historical data trend for Entasis Therapeutics Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entasis Therapeutics Holdings EPS without NRI Chart

Entasis Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Get a 7-Day Free Trial -8.05 -12.31 -3.33 -2.10 -1.09

Entasis Therapeutics Holdings Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.29 -0.26 -0.25 -0.32

Competitive Comparison of Entasis Therapeutics Holdings's EPS without NRI

For the Biotechnology subindustry, Entasis Therapeutics Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entasis Therapeutics Holdings's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entasis Therapeutics Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Entasis Therapeutics Holdings's PE Ratio without NRI falls into.



Entasis Therapeutics Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entasis Therapeutics Holdings  (NAS:ETTX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Entasis Therapeutics Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
35 Gatehouse Drive, Waltham, MA, USA, 02451
Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).
Executives
Theravance Inc 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner officer: VP, Principal Fin & Acct Off 35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac officer: Chief Medical Officer 35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch officer: Chief Fin. and Bus. Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller officer: Chief Development Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros director, officer: President and CEO C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi officer: Chief Scientific Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim officer: See Remarks 35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley officer: General Counsel C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola officer: Chief Commercial Officer 35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble officer: Chief Commercial Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451